Summary
Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
The global Insulin Glargine market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025.
Further key aspects of the report indicate that:
Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Market Size
Chapter 2: Global Production & Consumption Market by Type and End-Use
Chapter 3: Europe Production & Consumption Market by Type and End-Use
Chapter 4: America Production & Consumption Market by Type and End-Use
Chapter 5: Asia Production & Consumption Market by Type and End-Use
Chapter 6: Oceania Production & Consumption Market by Type and End-Use
Chapter 7: Africa Production & Consumption Market by Type and End-Use
Chapter 8: Global Market Forecast by Type, End-Use and Region
Chapter 9: Company information, Sales, Cost, Margin, news etc.
Chapter 10: Market Competition by Companies and Market Concentration Ratio
Chapter 11: Market Impact by Coronavirus.
Chapter 12: Industry Summary
.
Market Segment as follows:
Market Segment By Key Companies:
Sanofi-Aventis
Ganlee
Biocon
Market Segment By Type:
Single Dose Vial
Pre-filled Syringe
Market Segment By Application:
Treat type 1 diabetes
Treat type 2 diabetes
This report can be dispatched within 24-48 Hours.